These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 25066736)
21. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980 [TBL] [Abstract][Full Text] [Related]
22. Comparative study of the effects of aluminum adjuvants and Freund's incomplete adjuvant on the immune response to an Edwardsiella tarda major antigen. Jiao XD; Cheng S; Hu YH; Sun L Vaccine; 2010 Feb; 28(7):1832-7. PubMed ID: 20006568 [TBL] [Abstract][Full Text] [Related]
23. Prophylactic vaccination with adjuvant monophosphoryl lipid a prevents Th2-mediated murine asthmatic responses. Wu CJ; Chou HW; Liou CJ; Shen JJ; Wang LC; Kuo ML J Asthma; 2013 May; 50(4):327-33. PubMed ID: 23343407 [TBL] [Abstract][Full Text] [Related]
24. Ex-vivo expanded baboon CD4+ CD25 Hi Treg cells suppress baboon anti-pig T and B cell immune response. Singh AK; Seavey CN; Horvath KA; Mohiuddin MM Xenotransplantation; 2012; 19(2):102-11. PubMed ID: 22497512 [TBL] [Abstract][Full Text] [Related]
25. Updated aluminum pharmacokinetics following infant exposures through diet and vaccination. Mitkus RJ; King DB; Hess MA; Forshee RA; Walderhaug MO Vaccine; 2011 Nov; 29(51):9538-43. PubMed ID: 22001122 [TBL] [Abstract][Full Text] [Related]
26. Expanding and converting regulatory T cells: a horizon for immunotherapy. Khattar M; Chen W; Stepkowski SM Arch Immunol Ther Exp (Warsz); 2009; 57(3):199-204. PubMed ID: 19479206 [TBL] [Abstract][Full Text] [Related]
27. Bee venom ameliorates ovalbumin induced allergic asthma via modulating CD4+CD25+ regulatory T cells in mice. Choi MS; Park S; Choi T; Lee G; Haam KK; Hong MC; Min BI; Bae H Cytokine; 2013 Jan; 61(1):256-65. PubMed ID: 23121887 [TBL] [Abstract][Full Text] [Related]
28. Revisiting regulatory T cells in type 1 diabetes. Zhang Y; Bandala-Sanchez E; Harrison LC Curr Opin Endocrinol Diabetes Obes; 2012 Aug; 19(4):271-8. PubMed ID: 22732485 [TBL] [Abstract][Full Text] [Related]
29. Current adjuvants and new perspectives in vaccine formulation. Montomoli E; Piccirella S; Khadang B; Mennitto E; Camerini R; De Rosa A Expert Rev Vaccines; 2011 Jul; 10(7):1053-61. PubMed ID: 21806399 [TBL] [Abstract][Full Text] [Related]
30. Intraperitoneal administration of aluminium-based adjuvants produces severe transient systemic adverse events in mice. Freiberger SN; Leuthard DS; Duda A; Contassot E; Thallmair M; Kündig TM; Johansen P Eur J Pharm Sci; 2018 Mar; 115():362-368. PubMed ID: 29410031 [TBL] [Abstract][Full Text] [Related]
31. The adjuvant effect of TLR agonists on CD4(+) effector T cells is under the indirect control of regulatory T cells. Olivier A; Sainz-Perez A; Dong H; Sparwasser T; Majlessi L; Leclerc C Eur J Immunol; 2011 Aug; 41(8):2303-13. PubMed ID: 21538349 [TBL] [Abstract][Full Text] [Related]
32. Cytokines affecting CD4(+) T regulatory cells in transplant tolerance. Interleukin-4 does not maintain alloantigen specific CD4(+)CD25(+) Treg. Plain KM; Verma ND; Tran GT; Nomura M; Boyd R; Robinson CM; Hodgkinson SJ; Hall BM Transpl Immunol; 2013 Dec; 29(1-4):51-9. PubMed ID: 24139939 [TBL] [Abstract][Full Text] [Related]
33. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. Didierlaurent AM; Morel S; Lockman L; Giannini SL; Bisteau M; Carlsen H; Kielland A; Vosters O; Vanderheyde N; Schiavetti F; Larocque D; Van Mechelen M; Garçon N J Immunol; 2009 Nov; 183(10):6186-97. PubMed ID: 19864596 [TBL] [Abstract][Full Text] [Related]
34. Specific immunotherapy and turning off the T cell: how does it work? Ozdemir C; Kucuksezer UC; Akdis M; Akdis CA Ann Allergy Asthma Immunol; 2011 Nov; 107(5):381-92. PubMed ID: 22018608 [TBL] [Abstract][Full Text] [Related]
35. Mechanisms of allergen-specific immunotherapy: T-regulatory cells and more. Verhagen J; Blaser K; Akdis CA; Akdis M Immunol Allergy Clin North Am; 2006 May; 26(2):207-31, vi. PubMed ID: 16701141 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of the allergic response by regulatory T cells. Stock P; DeKruyff RH; Umetsu DT Curr Opin Allergy Clin Immunol; 2006 Feb; 6(1):12-6. PubMed ID: 16505606 [TBL] [Abstract][Full Text] [Related]
38. Molecular adjuvants that modulate regulatory T cell function in vaccination: A critical appraisal. Batista-Duharte A; Téllez-Martínez D; Fuentes DLP; Carlos IZ Pharmacol Res; 2018 Mar; 129():237-250. PubMed ID: 29175113 [TBL] [Abstract][Full Text] [Related]
39. A fusion protein of flagellin and ovalbumin suppresses the TH2 response and prevents murine intestinal allergy. Schülke S; Burggraf M; Waibler Z; Wangorsch A; Wolfheimer S; Kalinke U; Vieths S; Toda M; Scheurer S J Allergy Clin Immunol; 2011 Dec; 128(6):1340-1348.e12. PubMed ID: 21872305 [TBL] [Abstract][Full Text] [Related]
40. Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation. Suárez-Fueyo A; Ramos T; Galán A; Jimeno L; Wurtzen PA; Marin A; de Frutos C; Blanco C; Carrera AC; Barber D; Varona R J Allergy Clin Immunol; 2014 Jan; 133(1):130-8.e1-2. PubMed ID: 24290282 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]